LENZ THERAPEUTICS, INC. Inactive Instrument
LENZ Therapeutics, Inc. Stock OTC Markets
Equities
GRPH
US52635N1037
Biotechnology & Medical Research
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 12.77M | Capitalization | 402M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M | Net income 2025 * | -79M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 31.5 x |
| P/E ratio 2024 * |
-7.31
x | P/E ratio 2025 * |
-5.63
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.19% |
More Fundamentals
* Assessed data
More news
More press releases
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | +3.63% | - |
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |